Enanta Pharmaceuticals, a biotechnology firm, is committed to discovering and developing cutting-edge small molecule drugs to treat viral infections and liver diseases. Its disease targets include respiratory syncytial virus, human metapneumovirus, SARS-CoV-2, and hepatitis B virus. In collaboration with Abbott Laboratories, the firm is focused on identifying, developing, and commercializing HCV NS3 and NS3/4A protease inhibitor compounds such as glecaprevir and paritaprevir for treating chronic hepatitis C virus. Since its inception in 1995, Enanta Pharmaceuticals has established itself as an industry leader, with its corporate headquarters in Watertown, Massachusetts. With innovative research and development programs, the company remains dedicated to improving public health by offering innovative solutions for viral infections and liver diseases.
Enanta Pharmaceuticals's ticker is ENTA
The company's shares trade on the NASDAQ stock exchange
They are based in Watertown, Massachusetts
There are 51-200 employees working at Enanta Pharmaceuticals
It is enanta.com/Home/default.aspx
Enanta Pharmaceuticals is in the Healthcare sector
Enanta Pharmaceuticals is in the Biotechnology industry
The following five companies are Enanta Pharmaceuticals's industry peers: